A specific domain of the chikungunya virus E2 protein regulates particle formation in human cells: Implications for alphavirus vaccine design, J Virol, vol.86, pp.8879-8883, 2012. ,
A virus-like particle vaccine for epidemic chikungunya virus protects nonhuman primates against infection, Nat Med, vol.16, pp.334-338, 2010. ,
An in vitro assay to study chikungunya virus RNA synthesis and the mode of action of inhibitors, J Gen Virol, 2014. ,
Antiviral chlorinated daphnane diterpenoid orthoesters from the bark and wood of Trigonostemon cherrieri, Phytochemistry, vol.84, pp.160-168, 2012. ,
URL : https://hal.archives-ouvertes.fr/hal-00769790
Nonstructural protein 2 (nsP2) of chikungunya virus (CHIKV) enhances protective immunity mediated by a CHIKV envelope protein expressing DNA vaccine, Viral Immunol, vol.26, pp.75-83, 2013. ,
Computer-aided identification, design and synthesis of a novel series of compounds with selective antiviral activity against chikungunya virus, Antiviral Res, vol.98, pp.12-18, 2013. ,
URL : https://hal.archives-ouvertes.fr/pasteur-01054208
Neutralizing and non-neutralizing monoclonal antibodies to the E2 glycoprotein of Semliki Forest virus can protect mice from lethal encephalitis, J Gen Virol, vol.64, pp.1405-1408, 1983. ,
Monoclonal antibodies for prophylactic and therapeutic use against viral infections, Vaccine, vol.31, pp.1553-1559, 2013. ,
Prostratin and 12-O-tetradecanoylphorbol 13-acetate are potent and selective inhibitors of chikungunya virus replication, J Nat Prod, vol.75, pp.2183-2187, 2012. ,
URL : https://hal.archives-ouvertes.fr/hal-00785632
A recombinant measles vaccine expressing chikungunya viruslike particles is strongly immunogenic and protects mice from lethal challenge with chikungunya virus, Vaccine, vol.31, pp.3718-3725, 2013. ,
In vitro inhibition of chikungunya and Semliki Forest viruses replication by antiviral compounds: Synergistic effect of interferon-alpha and ribavirin combination, Antiviral Res, vol.61, pp.111-117, 2004. ,
Chikungunya: A re-emerging virus, Lancet, vol.379, pp.662-671, 2012. ,
A chimeric vesiculo/alphavirus is an effective alphavirus vaccine, J Virol, vol.87, pp.395-402, 2013. ,
Deciphering the protective role of adaptive immunity to CHIKV/IRES a novel candidate vaccine against chikungunya in the A129 mouse model, Vaccine, vol.31, pp.3353-3360, 2013. ,
Prophylaxis and therapy for chikungunya virus infection, J Infect Dis, vol.200, pp.516-523, 2009. ,
Identification of novel compounds inhibiting chikungunya virusinduced cell death by high throughput screening of a kinase inhibitor library, PLoS Negl Trop Dis, vol.7, p.2471, 2013. ,
URL : https://hal.archives-ouvertes.fr/pasteur-01108617
On chikungunya acute infection and chloroquine treatment, Vector Borne Zoonotic Dis, vol.8, pp.837-839, 2008. ,
Hepatitis C virus-specific directly acting antiviral drugs, Curr Top Microbiol Immunol, vol.369, pp.289-320, 2013. ,
Mutations in the chikungunya virus non-structural proteins cause resistance to favipiravir (T-705), a broad-spectrum antiviral, J Antimicrobiol Chemother, vol.69, pp.2770-2784, 2014. ,
In vitro antiviral activity of arbidol against chikungunya virus and characteristics of a selected resistant mutant, Antiviral Res, vol.90, pp.99-107, 2011. ,
Persistence in humans of antibody after immunization with four alphavirus vaccines, Asian J Infect Dis, vol.3, pp.119-124, 1979. ,
Exploring the native human antibody repertoire to create antiviral therapeutics, Curr Top Microbiol Immunol, vol.317, pp.155-183, 2008. ,
Phase II safety and immunogenicity study of live chikungunya virus vaccine TSI-GSD-218, Am J Trop Med Hyg, vol.62, pp.681-685, 2000. ,
Use of human monoclonal antibodies to treat chikungunya virus infection, J Infect Dis, vol.207, pp.319-322, 2013. ,
Favipiravir (T-705), a novel viral RNA polymerase inhibitor, Antiviral Res, vol.100, pp.446-454, 2013. ,
A novel poxvirus-based vaccine (MVA-CHIKV) is highly immunogenic and protects mice against chikungunya infection, J Virol, vol.88, pp.3527-3547, 2014. ,
Multidisciplinary prospective study of mother-to-child chikungunya virus infections on the island of La Reunion, PLoS Med, vol.5, p.60, 2008. ,
URL : https://hal.archives-ouvertes.fr/inserm-00700815
Neutralizing monoclonal antibodies to the E2 protein of chikungunya virus protects against disease in a mouse model, Clin Immunol, vol.149, pp.487-497, 2013. ,
Characterization of the cysteine protease domain of Semliki Forest virus replicase protein nsP2 by in vitro mutagenesis, FEBS Lett, vol.580, pp.1502-1508, 2006. ,
MVA and NYVAC as vaccines against emergent infectious diseases and cancer, Curr Gene Ther, vol.11, pp.189-217, 2011. ,
Attenuation of chikungunya virus vaccine strain 181/clone 25 is determined by two amino acid substitutions in the E2 envelope glycoprotein, J Virol, vol.86, pp.6084-6096, 2012. ,
Novel attenuated chikungunya vaccine candidates elicit protective immunity in C57BL/6 mice, J Virol, vol.88, pp.2858-2866, 2014. ,
Prime-boost immunization strategies against chikungunya virus, J Virol, vol.88, pp.13333-13343, 2014. ,
Production and evaluation of a formalin-killed chikungunya vaccine, J Immunol, vol.107, pp.643-647, 1971. ,
US Military contributions to the global response to pandemic chikungunya, Vaccine, vol.30, pp.6713-6720, 2012. ,
Longitudinal analysis of the human antibody response to chikungunya virus infection: Implications for serodiagnosis and vaccine development, J Virol, vol.86, pp.13005-13015, 2012. ,
Early neutralizing IgG response to chikungunya virus in infected patients targets a dominant linear epitope on the E2 glycoprotein, EMBO Mol Med, vol.4, pp.330-343, 2012. ,
Early appearance of neutralizing immunoglobulin G3 antibodies is associated with chikungunya virus clearance and long-term clinical protection, J Infect Dis, vol.205, pp.1147-1154, 2012. ,
Chikungunya virus: An update on antiviral development and challenges, Drug Discov Today, vol.18, pp.969-983, 2013. ,
Assessment of in vitro prophylactic and therapeutic efficacy of chloroquine against chikungunya virus in vero cells, J Med Virol, vol.82, pp.817-824, 2010. ,
Cellular IMPDH enzyme activity is a potential target for the inhibition of chikungunya virus replication and virus induced apoptosis in cultured mammalian cells, Antiviral Res, vol.89, pp.1-8, 2011. ,
Subunit vaccine formulations based on recombinant envelope proteins of chikungunya virus elicit balanced Th1/Th2 response and virus-neutralizing antibodies in mice, Virus Res, vol.167, pp.236-246, 2012. ,
Development of a stable virus-like particle vaccine formulation against chikungunya virus and investigation of the effects of polyanions, J Pharm Sci, vol.102, pp.4305-4314, 2013. ,
Evaluation of recombinant E2 protein-based and whole-virus inactivated candidate vaccines against chikungunya virus, Vaccine, vol.30, pp.6142-6149, 2012. ,
Guanosine nucleotide analogs as inhibitors of alphavirus mRNA capping enzyme, Antiviral Res, vol.42, pp.35-46, 1999. ,
Chikungunya virus neutralization antigens and direct cell-to-cell transmission are revealed by human antibody-escape mutants, PLoS Pathog, vol.7, p.1002390, 2011. ,
Development of an attenuated strain of chikungunya virus for use in vaccine production, Vaccine, vol.4, pp.157-162, 1986. ,
Inhibitors of virus replication: Recent developments and prospects, Appl Microbiol Biotechnol, vol.66, pp.612-621, 2005. ,
A DNA vaccine against chikungunya virus is protective in mice and induces neutralizing antibodies in mice and nonhuman primates, PLoS Negl Trop Dis, vol.5, p.928, 2011. ,
Novel therapies for hepatitis C: one pill fits all?, Nat Rev Drug Discov, vol.12, pp.595-610, 2013. ,
Role of complement and the Fc portion of immunoglobulin G in immunity to Venezuelan equine encephalomyelitis virus infection with glycoproteinspecific monoclonal antibodies, J Virol, vol.55, pp.594-600, 1985. ,
Immunologic interference from sequential administration of live attenuated alphavirus vaccines, J Infect Dis, vol.177, pp.634-641, 1998. ,
Functional processing and secretion of chikungunya virus E1 and E2 glycoproteins in insect cells, Virol J, vol.8, p.353, 2011. ,
Effective chikungunya virus-like particle vaccine produced in insect cells, PLoS Negl Trop Dis, vol.7, p.2124, 2013. ,
Chikungunya virus-like particles are more immunogenic in a lethal AG129 mouse model compared to glycoprotein E1 or E2 subunits, Vaccine, vol.31, pp.6092-6096, 2013. ,
Immunogenicity of novel consensus-based DNA vaccines against chikungunya virus, Vaccine, vol.26, pp.5128-5134, 2008. ,
Development of a highly protective combination monoclonal antibody therapy against chikungunya virus, PLoS Pathog, vol.9, p.1003312, 2013. ,
Crossprotective immunity against o'nyong-nyong virus afforded by a novel recombinant chikungunya vaccine, Vaccine, vol.30, pp.4638-4643, 2012. ,
Chikungunya virus host range E2 transmembrane deletion mutants induce protective immunity against challenge in C57BL/6J mice, J Virol, vol.87, pp.6748-6457, 2013. ,
Novel chikungunya vaccine candidate with an IRES-based attenuation and host range alteration mechanism, PLoS Pathog, vol.7, p.1002142, 2011. ,
Betulin-derived compounds as inhibitors of alphavirus replication, J Nat Prod, vol.72, pp.1917-1926, 2009. ,
Inhibitors of alphavirus entry and replication identified with a stable chikungunya replicon cell line and virus-based assays, PLoS One, vol.6, p.28923, 2011. ,
Chikungunya virus nsP3 & nsP4 interacts with HSP-90 to promote virus 256 ,
, Downloaded by Institut Pasteur from www.liebertpub.com at 01/22/20. For personal use only. replication: HSP-90 inhibitors reduce CHIKV infection and inflammation in vivo, Antiviral Res, vol.103, pp.7-16, 2014.
Chikungunya vaccine candidate is highly attenuated and protects nonhuman primates against telemetrically monitored disease following a single dose, J Infect Dis, vol.209, pp.1891-1899, 2014. ,
Characterization of purified Sindbis virus nsP4 RNA-dependent RNA polymerase activity in vitro, Virology, vol.384, pp.201-208, 2009. ,
Mutations that confer resistance to mycophenolic acid and ribavirin on Sindbis virus map to the nonstructural protein nsP1, Virology, vol.181, pp.490-499, 1991. ,
Protective monoclonal antibodies define maturational and pH-dependent antigenic changes in Sindbis virus E1 glycoprotein, Virology, vol.130, pp.144-154, 1983. ,
Characterization of synthetic chikungunya viruses based on the consensus sequence of recent E1-226V isolates, PLoS One, vol.8, p.71047, 2013. ,
A neutralizing monoclonal antibody targeting the acid-sensitive region in chikungunya virus E2 protects from disease, PLoS Negl Trop Dis, vol.7, p.2423, 2013. ,
Homology modeling, molecular dynamics, e-pharmacophore mapping and docking study of chikungunya virus nsP2 protease, J Mol Model, vol.18, pp.39-51, 2012. ,
Structural analyses at pseudo atomic resolution of chikungunya virus and antibodies show mechanisms of neutralization, Elife, vol.2, p.435, 2013. ,
Assessment of immunogenic potential of Vero adapted formalin inactivated vaccine derived from novel ECSA genotype of chikungunya virus, Vaccine, vol.27, pp.2513-2522, 2009. ,
DNA Vaccine initiates replication of live attenuated chikungunya virus in vitro and elicits protective immune response in mice, J Infect Dis, vol.209, pp.1882-1890, 2014. ,
Protective efficacy of modified vaccinia virus Ankara in preclinical studies, Vaccine, vol.31, pp.4235-4240, 2013. ,
Enhanced production of chikungunya virus-like particles using a high-pH adapted Sprodotera frugiperda insect cell line, PLoS One, vol.10, p.1371, 2014. ,
A complex adenovirus vaccine against chikungunya virus provides complete protection against viraemia and arthritis, Vaccine, vol.29, pp.2803-2809, 2011. ,
Chimeric alphavirus vaccine candidates for chikungunya, Vaccine, vol.26, pp.5030-5039, 2008. ,
Chimeric chikungunya viruses are nonpathogenic in highly sensitive mouse models but efficiently induce a protective immune response, J Virol, vol.85, pp.9249-9252, 2011. ,
Chikungunya virus and prospects for a vaccine, Expert Rev Vaccines, vol.11, pp.1087-1101, 2012. ,